Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Operations (2016 - 2025)

Editas Medicine (EDIT) has disclosed Cash from Operations for 11 consecutive years, with 30843000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 41.35% to 30843000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 179616000.0, a 1.18% increase, with the full-year FY2024 number at 210284000.0, down 59.09% from a year prior.
  • Cash from Operations was 30843000.0 for Q3 2025 at Editas Medicine, up from 50212000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 22240000.0 in Q4 2023 to a low of 57062000.0 in Q2 2024.
  • A 5-year average of 42761473.68 and a median of 42273000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 47.39% in 2023, then crashed 128.25% in 2024.
  • Editas Medicine's Cash from Operations stood at 34582000.0 in 2021, then fell by 22.24% to 42273000.0 in 2022, then surged by 47.39% to 22240000.0 in 2023, then plummeted by 128.25% to 50762000.0 in 2024, then skyrocketed by 39.24% to 30843000.0 in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Cash from Operations are 30843000.0 (Q3 2025), 50212000.0 (Q2 2025), and 47799000.0 (Q1 2025).